- Home
- PDT vs ORGO Comparison
PDT vs ORGO Comparison
Compare PDT & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDT
- ORGO
- Stock Information
- Founded
- PDT 1989
- ORGO 1985
- Country
- PDT United States
- ORGO United States
- Employees
- PDT N/A
- ORGO N/A
- Industry
- PDT Finance Companies
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- PDT Finance
- ORGO Health Care
- Exchange
- PDT Nasdaq
- ORGO Nasdaq
- Market Cap
- PDT 660.6M
- ORGO 620.3M
- IPO Year
- PDT N/A
- ORGO N/A
- Fundamental
- Price
- PDT $13.41
- ORGO $4.95
- Analyst Decision
- PDT
- ORGO Buy
- Analyst Count
- PDT 0
- ORGO 2
- Target Price
- PDT N/A
- ORGO $7.50
- AVG Volume (30 Days)
- PDT 145.6K
- ORGO 729.3K
- Earning Date
- PDT 01-01-0001
- ORGO 11-11-2025
- Dividend Yield
- PDT 8.88%
- ORGO N/A
- EPS Growth
- PDT N/A
- ORGO N/A
- EPS
- PDT N/A
- ORGO N/A
- Revenue
- PDT N/A
- ORGO $429,531,000.00
- Revenue This Year
- PDT N/A
- ORGO $2.57
- Revenue Next Year
- PDT N/A
- ORGO $9.80
- P/E Ratio
- PDT N/A
- ORGO N/A
- Revenue Growth
- PDT N/A
- ORGO N/A
- 52 Week Low
- PDT $8.77
- ORGO $2.48
- 52 Week High
- PDT $13.05
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- PDT 53.85
- ORGO 54.32
- Support Level
- PDT $13.35
- ORGO $4.75
- Resistance Level
- PDT $13.47
- ORGO $5.10
- Average True Range (ATR)
- PDT 0.10
- ORGO 0.21
- MACD
- PDT -0.00
- ORGO -0.01
- Stochastic Oscillator
- PDT 78.62
- ORGO 53.27
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.